Viatris has grown revenue −1.9% a year over three years and −1.1% a year over five. Revenue growth, 3-year annual rate: −1.9% (Drug Manufacturers - Specialty & Generic median +13%). Revenue growth, 5-year rate: −1.1%, growth has slowed since the five-year average. Years of annual history on file: 8, FY2018 to FY2025, as filed.

VTRSViatris

Healthcare

$17.66+84% 1Y

$17.66

$9.2352 weeks$18.27

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin widening (+19.6 points).

1 good, 1 neutral, 1 without data

Revenue trend+4% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −1% a year.

Margin direction+19.6 points operating

Trailing-twelve-month operating margin, -0.6% now against -20.3% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbehind 86% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is VTRS growing?

Viatris has grown revenue −1.9% a year over three years and −1.1% a year over five.

−1.9%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −1.1%
Revenue growth, 5-year rate · −1.9% over three · growth has slowed since the five-year average
Years of annual history on file: 8
Years of annual history on file · FY2018 to FY2025, as filed

Details›